• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pieris AG - Product Pipeline Review - H2 2011 Product Image

Pieris AG - Product Pipeline Review - H2 2011

  • ID: 1964386
  • November 2011
  • 44 pages
  • Global Markets Direct

Pieris AG – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Pieris AG - Product Pipeline Review - H2 2011” provides data on the Pieris AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pieris AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Pieris AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Pieris AG - Brief Pieris AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pieris AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- READ MORE >



List of Tables
List of Figures
Pieris AG Snapshot
Pieris AG Overview
Key Information
Key Facts
Pieris AG – Research and Development Overview
Key Therapeutic Areas
Pieris AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pieris AG – Pipeline Products Glance
Pieris AG Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Pieris AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Pieris AG – Drug Profiles
Angiocal
Product Description
Mechanism of Action
R&D Progress
PRS-080
Product Description
Mechanism of Action
R&D Progress
PRS-110
Product Description
Mechanism of Action
R&D Progress
Pieris AG – Pipeline Analysis
Pieris AG – Pipeline Products by Therapeutic Class
Pieris AG - Pipeline Products By Target
Pieris AG – Pipeline Products by Route of Administration
Pieris AG – Pipeline Products by Molecule Type
Pieris AG – Recent Pipeline Updates
Pieris AG – Locations And Subsidiaries
Head Office
Recent Developments
Mar 29, 2007: Pieris Demonstrates Potent Anti-Tumor Activity Of A VEGF-Specific Anticalin In Preclinical Studies
May 23, 2011: Pieris Announces Preclinical In Vitro And In Vivo Data For Anticalin PRS-080 Hepcidin Antagonist Drug Program
Feb 22, 2011: Pieris To Present Interim Date From Phase I Clinical Trial Of PRS-050 At Molecular Medicine Tri-Conference
Jul 16, 2008: Wacker Validates Scalability Of Anticalin Production With E.Coli Secretion Technology And Will Produce Pieris First Clinical Candidate PRS-050
Jun 15, 2010: Pieris Initiates Phase I Clinical Trial For PRS-050 In Patients With Solid Tumors
Jul 10, 2007: Pieris Progresses Proprietary Asthma Program, Validation Of Pulmonary Delivery Of Anticalin-based Protein Product Candidate
Nov 08, 2007: Pieris Strengthens Its Management, As It Prepares For The Clinical Development Of PRS-050, An Anticalin-Based Novel Cancer Therapy
Sep 05, 2007: Pieris Validates The Use Of Anticalins As Ophthalmologic Biotherapeutics
Feb 03, 2009: Pieris Reports Development Progress For Anticalin PRS-050, A Next Generation VEGF Antagonist
Financial Deals Landscape
Pieris AG, Deals Summary
Pieris AG, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Pieris Secures $38 Million In Series B Financing
PIERIS Secures $6.39 Million In Series B Financing
Pieris Secures $11.81 Million In Series A Financing
Partnerships
Pieris Enters Into Drug Discovery Collaboration With Takeda San Francisco
Pieris Enters Into Co-Development Agreement With Allergan
Pieris Enters Into Research Agreement With Pepscan Therapeutics
Pieris Enters Into Research Agreement With GE Healthcare
Pieris Enters Into Collaboration Agreement With Syngenta
Licensing Agreements
Pieris Enters Into Collaboration And Licensing Agreement With Daiichi Sankyo
Pieris Signs Licensing Agreement With Sanofi-Aventis And Sanofi Pasteur
Pieris Enters Into Licensing Agreement With Allergan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Pieris AG – Pipeline by Therapy Area and Indication, H2 2011
Pieris AG – Pipeline by Stage of Development, H2 2011
Pieris AG – Monotherapy Products in Pipeline, H2 2011
Pieris AG - Phase I, H2 2011
Pieris AG - Pipeline By Therapeutic Class, H2 2011
Pieris AG - Pipeline By Target, H2 2011
Pieris AG – Pipeline By Route of Administration, H2 2011
Pieris AG – Pipeline By Molecule Type, H2 2011
Pieris AG – Recent Pipeline Updates, H2 2011
Pieris AG, Deals Summary
Pieris Secures $38 Million In Series B Financing
PIERIS Secures $6.39 Million In Series B Financing
Pieris Secures $11.81 Million In Series A Financing
Pieris Enters Into Drug Discovery Collaboration With Takeda San Francisco
Pieris Enters Into Co-Development Agreement With Allergan
Pieris Enters Into Research Agreement With Pepscan Therapeutics
Pieris Enters Into Research Agreement With GE Healthcare
Pieris Enters Into Collaboration Agreement With Syngenta
Pieris Enters Into Collaboration And Licensing Agreement With Daiichi Sankyo
Pieris Signs Licensing Agreement With Sanofi-Aventis And Sanofi Pasteur
Pieris Enters Into Licensing Agreement With Allergan

List of Figures
Pieris AG – Pipeline by Therapy Area and Indication, H2 2011
Pieris AG – Pipeline by Stage of Development, H2 2011
Pieris AG – Monotherapy Products in Pipeline, H2 2011
Pieris AG – Pipeline By Therapeutic Class, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos